Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year

You may also be interested in...

Exclusive: U.S. Chamber Lobbies Against China Drug Registration Revisions That Would Favor Local Generics

The U.S. Chamber of Commerce is lobbying China FDA over its recent draft drug registration regulations, which would allow approval of generics while an originator’s patent is still valid. Big pharma could face faster and stronger generic competition in China if CFDA finalizes the regulations without revision.

China Looks To Amend Drug Registration Regulation With Bolar Exemption That Favors Generics

China FDA released a draft regulation on drug registration that formalizes the “Bolar Exemption,” but the approach taken is unbalanced, according to experts, and would end up favoring generic competitors.

PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 2 Of 2)

Lee Babiss left his position as president of pharmaceutical research at Roche to become the executive vice president of global laboratory services at the Wilmington, North Carolina-based contract research organization PPD. In part one of an interview with PharmAsia News, Babiss spoke about the evolving relationships between pharmaceutical firms and CROs, including end-to-end virtualization of R&D (PharmAsia News, April 6, 2010).

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts